Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -.--% | -100.00% |
05-31 | SMITH & NEPHEW : EPS cut (2023: +8.0%, 2024: -16.2%) | |
05-14 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading | MT |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-100.00% | 10.99B | - | ||
+13.73% | 130B | A- | ||
-4.33% | 8.35B | C | ||
+41.80% | 5.67B | B+ | ||
-21.94% | 4.72B | C | ||
+7.81% | 3.42B | C- | ||
-10.26% | 2.76B | B- | ||
-10.29% | 2.11B | - | - | |
-13.58% | 1.92B | - | ||
-27.77% | 1.68B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SN. Stock
- SN. Stock
- Ratings Smith & Nephew plc